Literature DB >> 2969116

Direct argon laser exposure for recanalization of peripheral arteries: early results.

L A Nordstrom1, W R Castaneda-Zuniga, E G Young, K B Von Seggern.   

Abstract

Direct laser light, in combination with percutaneous transluminal angioplasty (PTA), was used to recanalize atherosclerotic peripheral arteries. Argon laser energy was controlled with an optical assembly and aligned with a special centering/dilation balloon so that plaque tissue absorbed laser energy directly and was vaporized. A channel was thereby created with multiple 10-W laser exposures (2-10 seconds), and conventional angioplasty was then performed. Recanalization was achieved in 33 of 36 procedures (92%), in 23 femoropopliteal (mean length, 9 cm) and three iliac total occlusions and ten femoropopliteal high-grade stenoses, with the three failures occurring in the first group. Complications included two emboli, six moderate groin hematomas, and one laser perforation. While these results are preliminary (mean follow-up, 3 months), direct laser angioplasty appears to be a useful adjunct to PTA for treating atherosclerotic arteries.

Entities:  

Mesh:

Year:  1988        PMID: 2969116     DOI: 10.1148/radiology.168.2.2969116

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Intravascular ultrasound imaging for guidance of atherectomy and other plaque removal techniques.

Authors:  P G Yock; P J Fitzgerald; K Sudhir; D T Linker; W White; A Ports
Journal:  Int J Card Imaging       Date:  1991

2.  Total occlusion of iliac arteries: results of balloon angioplasty.

Authors:  A K Gupta; K Ravimandalam; V R Rao; S Joseph; M Unni; A S Rao; K S Neelkandhan
Journal:  Cardiovasc Intervent Radiol       Date:  1993 May-Jun       Impact factor: 2.740

3.  Laser-assisted balloon angioplasty in complete femoropopliteal occlusions: preliminary results.

Authors:  I P Arlart; A Gerlach; H G Grass
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jul-Aug       Impact factor: 2.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.